ARKG is trading at $49.69 (-3.15%); no clear healthcare-wide negative catalyst surfaced. - Biotech and healthcare had recently outperformed, with biotech news supporting gains in vaccine-related shares. - Broader markets were mixed as investors awaited Wednesday’s CPI report, which does not clearly explain ARKG’s sharper decline. - Genomics-focused holdings may be weighing on the fund, but available evidence identifies no specific holding-level trigger.